Global Markets

Symbiosis ups aseptic capacity by 25%; plans to expand further in 2020

The expansion addresses sustained demand particularly for cell and gene therapy services, says Scottish CDMO Symbiosis. Contract development and manufacturing organization (CDMO) Symbiosis Pharmaceutical Services has completed a £1.5 million ($1.8 million) expansion at its site in Stirling, UK – about 40 miles northwest of Scottish capital Edinburgh. The investment increases the firm’s output by about 25%, CEO Colin MacKay told this publication, and will help feed the demand aseptic GMP manufacturing (fill/finish) services. “Expansion of the business relates specifically…

The 12 trends of Christmas: A look back at 2019

CAR-T partnerships, Biopharma megamergers, biotech funding, and an eye on China. Bioprocess Insider presents the biggest stories of the year… through song! T’was the days before Christmas, And all through the dept. Not a story was breaking and journalists wept. So why not look back at the news of the year, The editor suggested over a beer… In the past twelve months Bioprocess Insider brought to you (To the tune of traditional Christmas song ‘The Twelve Days of Christmas’): A…

Samsung BioLogics brings Berkeley Lights’ Beacon to Korea

Korean CDMO Samsung BioLogics will use the Beacon optofluidic platform to reduce cell line development timelines and boost its drug development services. Having first entered the contract development space in 2017, Samsung BioLogics has now inked a deal to use Berkeley Lights’ Beacon pre-programable and automated optofluidic platform to service its customers cell line and process development projects. The technology itself is based on a nanofluidic chip consisting of chambers in which cells are placed to be cultured and assayed,…

WuXi Biologics establishes microbial fermentation in latest expansion

Having rapidly built up its mammalian biomanufacturing network, WuXi Biologics says it will now add microbial fermentation to its CDMO offering. At the end of October this year, Chinese contract development and manufacturing organization (CDMO) WuXi Biologics announced its latest financing round with intentions to raise roughly HK$3,950 million ($500 million). The supporting document states: “The Company intends to apply the net proceeds from the Primary Placing to support its development of vaccines and microbial based products as well as…

GE and Guangzhou gov bring bioprocess training to China

A single-use bioprocessing training facility in Guangzhou will help attract and retain biopharma talent in the burgeoning China market, says GE Healthcare. Bioprocess vendor GE Healthcare Life Sciences and Guangzhou Development District government have invested a total of $10 million (€9 million) to establish a biomanufacturing training center in the Guangdong province in China. The Guangzhou Bioprocess Academy aims to train over 1,000 people annually when it opens in September next year and is needed to feed the the rapid…

Boston next-gen manufacturing hub will ease bottlenecks, consortium

Cell and viral vector backlogs reduce patient access to next-generation medicines and slow R&D says the consortium behind a $50 million innovation hub. The group, led by Harvard University, made the comments this week, explaining that while some contract development and manufacturing organizations (CDMOs) offer cell line and vector services, growing demand means developers can face delays. “Manufacturing backlogs are slowing the production of cells that are essential to research, holding up the availability of new treatments headed for the…

Lack of UK cell and gene therapy skills a concern according to CGTC survey

UK cell and gene therapy firms are worried a shortage of skilled manufacturing staff will slow growth with some concerned Brexit will exacerbate the problem. The findings come from a new skills survey by the Cell and Gene Therapy Catapult (CGTC) – an organisation set up to support the sector by non-departmental government body, Innovate UK. Of the 41 companies that responded, 98% said they planned to expand their headcount over the next five years. Of these, 83% raised concerns…

CBMG hopes to bring China success to Maryland but is it late to the CAR-T party?

Cellular Biomedicine Group (CBMG) says it hopes to leverage R&D work done in China to expedite clinical trials in the US as it establishes facilities in Maryland. Last month, Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) announced plans to build a 22,000 square foot facility in Rockville, Maryland. The site will be the first outside China for the firm and is intended to initially support US clinical trials for its cell-based candidates targeting hematological indications. Speaking on its Q3 2019 conference…

China: Stainless-steel will shine as market moves to commercial

There has been a barrage of investment in flexible single-use capacity in the burgeoning China market. But as the sector matures and projects move to commercial, developers are likely to opt for fixed stainless-steel facilities, says BioPlan Associates. Biomanufacturing in China is blossoming, driven by changing regulations and a surge in investment, which have created a pathway for Market Authorization Holders (MAHs) and domestic third-party manufacturers alike. In the recent CPhI Worldwide annual report, Vicky Qing XIA, senior project manager…

German plant fastest option to make approved Ebola vaccine, says Merck

Merck & Co expects to complete production of the first batches of Ervebo – its newly EC-licensed Ebola vaccine – at its Burgwedel plant by late 2020. The European Commission (EC) granted Ervebo conditional marketing authorization for the active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus this week. The decision was based on data submitted for accelerated assessment in March. Merck – which is known as…